Browse public LH signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Labcorp reported strong Q3 results with EPS of $4.78 on $3.81B in sales, beating estimates. The company raised its 2026 guidance and expanded its diagnostics portfolio via acquisitions of BioReference Health assets, Myriad Prenatal Health, and Millennium Health, supporting margin gains. Management cited PAMA-related headwinds but expects accretive deals and LaunchPad initiatives to offset, helping LH extend its rally to new highs.
View signal analysis →Labcorp will acquire Myriad's Prenatal Health testing business for $210 million in cash plus inventory value at closing, expanding Labcorp's prenatal diagnostics footprint. The portfolio includes Prequel, Foresight, SneakPeek, and FirstGene tests, signaling a meaningful near-term uplift in Labcorp's reproductive health offerings and potential cross-selling opportunities after closing.
View signal analysis →Labcorp will acquire BioReference Health's clinical and specialty testing assets, including the 4Kscore Test, for $722 million cash with a potential $150 million earnout. The deal adds 80+ service centers and broadens Labcorp's portfolio in women's health, urology, and diagnostic analytics, with management projecting about $250 million in first-year revenue after closing, subject to regulatory approvals.
View signal analysis →Labcorp reaffirmed its 2026 targets and outlined a constructive, multi-year growth trajectory, including 5-8% revenue CAGR and 8.5-11.5% EPS CAGR through 2029. The plan emphasizes specialty testing, stronger health-system partnerships, personalized health solutions, and AI/robotics integration. Despite beating guidance, shares declined about 3.7% on the day, signaling mixed short-term reception to the long-term roadmap.
View signal analysis →Labcorp reported stronger-than-expected Q2 results and raised its full-year profit forecast, driven by steady diagnostic-testing demand and growth in its drug-development services (CDMO) segment. The print underscores resilience in core lab operations and a higher-margin CDMO mix, potentially supporting earnings upside and multiple expansion if demand remains durable.
View signal analysis →Labcorp Holdings reported a solid Q1 with earnings of $4.25, exceeding analysts' forecasts. The company also raised its full-year EPS guidance, reflecting confidence driven by technology investments aimed at improving operational efficiency.
View signal analysis →
